constella
abbvie deutschland gmbh & co. kg - linaclotide - Ärsyttävä suolen oireyhtymä - ummetuslääkkeet - constella on tarkoitettu aikuisille keskivaikean tai vaikean ärtyvän suolen oireyhtymän ja ummetuksen (ibs-c) oireenmukaiseen hoitoon.
lumigan
abbvie deutschland gmbh & co. kg - bimatoprosti - glaucoma, open-angle; ocular hypertension - prostaglandin analogues, ophthalmologicals - kohonnut silmänsisäinen paine kroonisessa avoimessa kulmassa glaukoomassa ja silmän kohonnut verenpaine (monoterapiana tai lisävaihdunnassa beetasalpaajille).
tepkinly
abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastiset aineet - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.
maviret
abbvie deutschland gmbh co. kg - glecaprevir, pibrentasvir - hepatiitti c, krooninen - antiviraalit systeemiseen käyttöön - maviret is indicated for the treatment of chronic hepatitis c virus (hcv) infection in adults and children aged 3 years and older. maviret coated granules is indicated for the treatment of chronic hepatitis c virus (hcv) infection in children 3 years and older.
ganfort
abbvie deutschland gmbh & co. kg - bimatoprostille, timololille - glaucoma, open-angle; ocular hypertension - silmätautien - silmänsisäisen paineen (iop) vähentäminen potilailla, joilla on avoin kulma glaukooma tai okulaarinen hypertensio, jotka eivät riittävästi vastaa paikallisia beetasalpaajia tai prostaglandiinianalogeja.
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leukemia, lymfosyyttinen, krooninen, b-solu - antineoplastiset aineet - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
xydalba
abbvie deutschland gmbh & co. kg - dalbavancin hydrochloride - soft tissue infections; skin diseases, bacterial - systeemiset bakteerilääkkeet, - akuuttien bakteerien iho- ja ihorakenteiden infektiot (absssi) hoito aikuisilla.
ozurdex
abbvie deutschland gmbh & co. kg - deksametasoni - macular edema; uveitis - ophthalmologicals, other ophthalmologicals - ozurdex on tarkoitettu aikuisille potilaille, joilla on silmänpohjan turvotus seuraavat joko haara verkkokalvon-laskimon tukos (brvo) tai verkkokalvon-laskimotukos (crvo). ozurdex on tarkoitettu aikuisille potilaille, joilla on tulehdus taka-segmentin silmän esittelee sekä tartunnallisia uveiitti. ozurdex on tarkoitettu aikuisille potilaille, joilla on näkövamma, koska diabeettinen makulaturvotus (dme), jotka ovat pseudofakiapotilailla tai jotka katsotaan riittävän herkkä, tai sopimaton ei-kortikosteroidihoito.
viekirax
abbvie deutschland gmbh co. kg - ombitasvir, paritaprevir, ritonaviiri - hepatiitti c, krooninen - antiviraalit systeemiseen käyttöön - viekirax on tarkoitettu yhdistettynä muiden lääkkeiden kanssa kroonisen hepatiitin c (chc) hoitoon aikuisilla. hepatiitti c-virus (hcv) genotyyppi spesifinen aktiivisuus.
skyrizi
abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosuppressantit - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.